Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ707MR)

This product GTTS-WQ707MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ707MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9261MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ1611MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ12458MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ12091MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ6569MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ14294MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ3618MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ11693MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MHAB5553A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW